EYPT on Nasdaq
EyePoint Pharmaceuticals
American pharmaceuticals company
EyePoint Pharmaceuticals Inc. (formerly pSivida Corporation) is a Watertown, Massachusetts company specialising in the application of microelectromechanical systems (MEMS) and nanotechnology to drug delivery.3 From Wikipedia, CC BY-SA 4.0
Price unavailable
Last updated Oct 18, 2026.
Overview
Compare with RAPID MICRO BIOSYSTEMS, INC., BioNano Genomics or Precipio, Inc., or pick any stock.
- TickerEYPT on Nasdaq1
- Industrypharmaceutical industry1
- HeadquartersWatertown1
- Websitewww.psivida.com
- Legal formDelaware corporation1
- Incorporated inDE4
- Business address480 Pleasant Street, Suite C400, Watertown, Ma 024724
- Filer categoryNon-accelerated filer, Smaller reporting company4
See how the biggest companies compare on our leaderboards
EyePoint Pharmaceuticals Inc. (formerly pSivida Corporation) is a Watertown, Massachusetts company specialising in the application of microelectromechanical systems (MEMS) and nanotechnology to drug delivery.3
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
-776.0%Operating margin5
-739.4%Net margin5
-27.5%Revenue growth, 20255
-75.8%Return on equity5
-$243.4MFree cash flow5
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
License and Collaboration Agreement brought in 53% of the revenue EyePoint Pharmaceuticals broke down this way in fiscal 2025.
Products and services by year
| Products and services | 2024 | 2025 |
|---|---|---|
| License and Collaboration Agreement | $38.5M | $16.7M |
| Royalty | $1.6M | $13.0M |
| YUTIQ Product | $3.1M | $1.6M |
Regions
United States brought in 96% of the revenue EyePoint Pharmaceuticals broke down this way in fiscal 2025.
Regions by year
| Regions | 2024 | 2025 |
|---|---|---|
| United States | $42.0M | $30.0M |
| [Canada] | $1.1M | $1.3M |
| United Kingdoms | $100.0K | $100.0K |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Research and development100¢$221.0M
- Income tax0¢$279.0K
Out of $31.4M in revenue.5 The company lost money this year.
Financial statements
Every line of the income statement as filed: the last 2 fiscal years, latest first.5
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Total revenues | $31.4M | $43.3M |
| Cost of sales | $2.1M | $3.7M |
| Research and development | $221.0M | $132.9M |
| Sales and marketing | $90.0K | $131.0K |
| General and administrative | $51.6M | $52.4M |
| Total operating expenses | $274.8M | $189.1M |
| Loss from operations | -$243.4M | -$145.9M |
| Interest and other income, net | $11.8M | $15.1M |
| Interest expense | -$33.0K | -$14.0K |
| Loss on extinguishment of debt | $0 | $0 |
| Total other income, net | $11.8M | $15.1M |
| Net loss before income taxes | -$231.7M | -$130.8M |
| Provision for income taxes | -$279.0K | -$90.0K |
| Net loss | -$232.0M | -$130.9M |
| Net loss per share - basic | -$3.17 | -$2.32 |
| Net loss per share - diluted | -$3.17 | -$2.32 |
| Weighted average common shares outstanding - basic | 73.3K shares | 56.3K shares |
| Weighted average common shares outstanding - diluted | 73.3K shares | 56.3K shares |
| Unrealized gain (loss) on available-for-sale securities | -$67.0K | $164.0K |
| Comprehensive income (loss) | -$232.0M | -$130.7M |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 3 fiscal years (annual) or 3 quarters (quarterly), latest first.5
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $101.8M | $99.7M | |
| Marketable securities | $204.3M | $271.2M | |
| Accounts and other receivables, net | $651.0K | $607.0K | |
| Prepaid expenses and other current assets | $20.1M | $9.5M | |
| Inventory | $1.8M | $2.3M | |
| Total current assets | $328.7M | $383.3M | |
| Property and equipment, net | $9.0M | $8.2M | |
| Operating lease right-of-use assets | $20.2M | $21.0M | |
| Restricted cash | $150.0K | $150.0K | |
| Other assets | $5.9M | $5.8M | |
| Total assets | $364.0M | $418.5M | |
| Accounts payable | $10.5M | $11.7M | |
| Accrued expenses | $24.4M | $18.1M | |
| Deferred revenue | $0 | $17.8M | |
| Other current liabilities | $2.1M | $1.4M | |
| Total current liabilities | $37.0M | $49.0M | |
| Deferred revenue - noncurrent | $0 | $10.9M | |
| Operating lease liabilities - noncurrent | $20.8M | $21.9M | |
| Other noncurrent liabilities | $87.0K | $205.0K | |
| Total liabilities | $57.9M | $82.0M | |
| Preferred stock, $.001 par value, 5,000,000 shares authorized, no shares issued and outstanding | $0 | $0 | |
| Common stock, $.001 par value, 300,000,000 shares authorized at December 31, 2025 and December 31, 2024; 82,826,416 and 68,266,005 shares issued and outstanding at December 31, 2025 and 2024, respectively | $83.0K | $68.0K | |
| Additional paid-in capital | $1.4B | $1.2B | |
| Accumulated deficit | -$1.1B | -$873.0M | |
| Accumulated other comprehensive income (loss) | $961.0K | $1.0M | |
| Total stockholders equity | $306.1M | $336.5M | $266.3M |
| Total liabilities and stockholders equity | $364.0M | $418.5M | |
| Preferred stock, par value | $0.00 | $0.00 | |
| Preferred stock, shares authorized | 5.0M shares | 5.0M shares | |
| Preferred stock, shares issued | 0 shares | 0 shares | |
| Preferred stock, shares outstanding | 0 shares | 0 shares | |
| Common stock, par value | $0.00 | $0.00 | |
| Common stock, shares authorized | 300.0M shares | 300.0M shares | |
| Common stock, shares issued | 82.8M shares | 68.3M shares | |
| Common stock, shares outstanding | 82.8M shares | 68.3M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $101.8M | $99.7M | |
| Marketable securities | $204.3M | $271.2M | |
| Accounts and other receivables, net | $651.0K | $607.0K | |
| Prepaid expenses and other current assets | $20.1M | $9.5M | |
| Inventory | $1.8M | $2.3M | |
| Total current assets | $328.7M | $383.3M | |
| Property and equipment, net | $9.0M | $8.2M | |
| Operating lease right-of-use assets | $20.2M | $21.0M | |
| Restricted cash | $150.0K | $150.0K | |
| Other assets | $5.9M | $5.8M | |
| Total assets | $364.0M | $418.5M | |
| Accounts payable | $10.5M | $11.7M | |
| Accrued expenses | $24.4M | $18.1M | |
| Deferred revenue | $0 | $17.8M | |
| Other current liabilities | $2.1M | $1.4M | |
| Total current liabilities | $37.0M | $49.0M | |
| Deferred revenue - noncurrent | $0 | $10.9M | |
| Operating lease liabilities - noncurrent | $20.8M | $21.9M | |
| Other noncurrent liabilities | $87.0K | $205.0K | |
| Total liabilities | $57.9M | $82.0M | |
| Preferred stock, $.001 par value, 5,000,000 shares authorized, no shares issued and outstanding | $0 | $0 | |
| Common stock, $.001 par value, 300,000,000 shares authorized at December 31, 2025 and December 31, 2024; 82,826,416 and 68,266,005 shares issued and outstanding at December 31, 2025 and 2024, respectively | $83.0K | $68.0K | |
| Additional paid-in capital | $1.4B | $1.2B | |
| Accumulated deficit | -$1.1B | -$873.0M | |
| Accumulated other comprehensive income (loss) | $961.0K | $1.0M | |
| Total stockholders equity | $306.1M | $336.5M | $266.3M |
| Total liabilities and stockholders equity | $364.0M | $418.5M | |
| Preferred stock, par value | $0.00 | $0.00 | |
| Preferred stock, shares authorized | 5.0M shares | 5.0M shares | |
| Preferred stock, shares issued | 0 shares | 0 shares | |
| Preferred stock, shares outstanding | 0 shares | 0 shares | |
| Common stock, par value | $0.00 | $0.00 | |
| Common stock, shares authorized | 300.0M shares | 300.0M shares | |
| Common stock, shares issued | 82.8M shares | 68.3M shares | |
| Common stock, shares outstanding | 82.8M shares | 68.3M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.5
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$232.0M | -$130.9M |
| Depreciation of property and equipment | $2.3M | $1.5M |
| Amortization of debt discount and premium and discount on available-for-sale marketable securities | -$4.8M | -$6.0M |
| Stock-based compensation | $27.9M | $36.7M |
| Deferred income tax | $279.0K | $90.0K |
| Accounts receivable and other current assets | -$10.7M | -$244.0K |
| Other assets | -$113.0K | -$5.8M |
| Inventory | $492.0K | $1.6M |
| Accounts payable and accrued expenses | $4.7M | $5.7M |
| Right-of-use assets and operating lease liabilities | $500.0K | $1.6M |
| Deferred revenue | -$28.6M | -$30.6M |
| Other noncurrent liabilities | -$33.0K | $0 |
| Net cash (used in) provided by operating activities | -$240.1M | -$126.2M |
| Purchases of marketable securities | -$252.0M | -$398.3M |
| Sales and maturities of marketable securities | $323.7M | $183.0M |
| Purchases of property and equipment | -$3.3M | -$4.1M |
| Proceeds from sale of property and equipment | $155.0K | $0 |
| Net cash (used in) provided by investing activities | $68.6M | -$219.4M |
| Proceeds from issuance of stock | $173.4M | $163.3M |
| Payment of equity issue costs | -$543.0K | -$672.0K |
| Net settlement of stock units to satisfy statutory tax withholding | -$1.4M | -$4.5M |
| Proceeds from exercise of stock options and employee stock purchase plan | $2.2M | $6.0M |
| Principal payments on finance lease obligations | -$105.0K | -$105.0K |
| Net cash (used in) provided by financing activities | $173.6M | $164.0M |
| Net (decrease) increase in cash, cash equivalents and restricted cash | $2.1M | -$181.6M |
| Lease liability arising from obtaining right-of-use assets | $903.0K | $17.5M |
| Stock issuance costs | $316.0K | $311.0K |
No quarter-by-quarter statement was filed.
Leadership
Who has led EyePoint Pharmaceuticals, and when. Pick a name to see everywhere that person has worked.
Chief financial officer
Chief operating officer
2010201520202025
- Chief executive officerJay S. Duker Jul 12, 2023 to now13
- Chief executive officerNancy Lurker Sep 20, 2016 to Jun 22, 202314
- Chief executive officerPaul Ashton Nov 20, 2009 to Mar 22, 201615
- PresidentJay S. Duker Jan 10, 2023 to now16
- PresidentNancy Lurker Sep 20, 2016 to Mar 2, 202214
- PresidentPaul Ashton Nov 20, 2009 to Mar 22, 201615
- Chief financial officerGeorge Elston Nov 18, 2019 to now17
- Chief financial officerMichael Soja Aug 27, 2007 to Sep 12, 200818
- Chief operating officerJay S. Duker Nov 3, 2021 to Jun 22, 202319
Board members and other officers (30)
- Chief Medical OfficerRamiro Ribeiro Mar 4, 2024 to now20
- Chief Corp Dev.&Strat. OfficerMichael Craig Pine Jan 14, 2022 to Jan 9, 202421
- OfficerNancy Lurker Feb 11, 2021 to Jul 12, 202422
- OfficerLeonard M. Blum May 16, 2018 to May 16, 201823
- Chief Medical OfficerDario A. Paggiarino Aug 3, 2016 to Apr 2, 202424
- EVP, Corp. & Comm'l Dev.Debora Jorn Nov 4, 2016 to Jun 29, 201725
- Corporate ControllerLeonard S. Ross Mar 27, 2009 to Jun 28, 201926
- SecretaryAaron Finlay Aug 27, 2007 to Oct 22, 200727
- VP Corp Affairs,Gen Coun & SecLori Freedman Aug 27, 2007 to Jul 25, 201628
- Managing DirectorPaul Ashton Aug 27, 2007 to Nov 20, 200829
- Board memberReginald J. Sanders Jan 8, 2025 to now30
- Board memberFred Hassan Sep 5, 2024 to now31
- Board memberStuart Duty Oct 17, 2023 to now32
- Board memberTherapeutics Ocumension Dec 7, 2023 to Jan 16, 202433
- Board memberAnthony P. Adamis Jun 27, 2022 to Jun 25, 202434
- Board memberKaren L. Zaderej Jul 13, 2022 to now35
- Board memberDavid R. Guyer Jan 29, 2019 to Jul 16, 202436
- Board memberWendy F. Dicicco Jul 16, 2019 to now37
- Board memberRonald W. Eastman Mar 30, 2018 to Mar 30, 201838
- Board memberGoran Ando Jun 27, 2018 to now39
- Board memberJohn B. Landis Oct 29, 2018 to now40
- Board memberKristine Peterson Jun 30, 2017 to Mar 3, 202041
- Board memberJay S. Duker Sep 27, 2016 to now42
- Board memberNancy Lurker Dec 14, 2016 to now43
- Board memberDouglas Evan Godshall Mar 13, 2012 to Jun 23, 202144
- Board memberPaul Hopper Jul 21, 2008 to Dec 20, 201345
- Board memberPeter G. Savas Jul 21, 2008 to Dec 4, 201546
- Board memberDavid J. Mazzo Aug 27, 2007 to Mar 3, 202047
- Board memberKatherine Woodthorpe Aug 27, 2007 to Jun 27, 200848
- Board memberPaul Ashton Aug 27, 2007 to Mar 22, 201629
Subsidiaries and ownership
Subsidiaries
- EyePoint Pharmaceuticals (United Kingdom)
From Wikidata.1
Former names
Timeline
Filings
422 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 91 major events, 193 insider forms, 50 large holders, 68 other. The latest 20:
- Oct 7, 2026SCHEDULE 13G/A EDGAR
- Sep 10, 20268-K EDGAR
- Sep 8, 2026SCHEDULE 13G EDGAR
- Aug 24, 20264 PRIMARY DOCUMENT EDGAR
- Aug 18, 20264 PRIMARY DOCUMENT EDGAR
- Aug 17, 20268-K EDGAR
- Aug 14, 2026SCHEDULE 13G/A EDGAR
- Aug 12, 2026SCHEDULE 13G EDGAR
- Aug 5, 2026S-8 EDGAR
- Aug 5, 202610-Q EDGAR
- Aug 5, 20268-K EDGAR
- Jul 31, 2026SCHEDULE 13G EDGAR
- Jul 30, 20268-K EDGAR
- Jul 28, 2026SCHEDULE 13G/A EDGAR
- Jul 22, 2026144/A EDGAR
- Jul 22, 2026144/A EDGAR
- Jul 21, 2026144 EDGAR
- Jul 17, 20268-K EDGAR
- Jul 14, 20264 PRIMARY DOCUMENT EDGAR
- Jul 2, 20264 PRIMARY DOCUMENT EDGAR
The 422 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last three years, summarized. The full record is on SEC EDGAR.
Insider trades and holders
Large holders
Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 50 such filings since October 2021, the latest 10:
- Oct 7, 2026SCHEDULE 13G/A
- Sep 8, 2026SCHEDULE 13G
- Aug 14, 2026SCHEDULE 13G/A
- Aug 12, 2026SCHEDULE 13G
- Jul 31, 2026SCHEDULE 13G
- Jul 28, 2026SCHEDULE 13G/A
- Jun 3, 2026SCHEDULE 13G
- May 15, 2026SCHEDULE 13G/A
- May 13, 2026SCHEDULE 13G/A
- Mar 26, 2026SCHEDULE 13G/A
From Forms 4 and Schedules 13D and 13G filed with the SEC.
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| Montanova Capital, LLC | 8,296,375 | $118.6M | 2.5% | No change |
| BlackRock, Inc. | 7,463,197 | $106.7M | 0.0% | +285,860 |
| Cormorant Asset Management, LP | 7,000,000 | $100.1M | 5.1% | −1,265,000 |
| Federated Hermes, Inc. | 5,681,052 | $81.2M | 0.1% | +11,463 |
| Adage Capital Partners Gp, L.l.c. | 4,827,792 | $69.0M | 0.1% | +1,527,792 |
| Franklin Resources Inc | 4,807,078 | $68.7M | 0.0% | −241,520 |
| Commodore Capital LP | 4,600,000 | $65.8M | 3.9% | +1,775,000 |
| Jupiter Topco LLC | 3,770,381 | $53.9M | 0.0% | New |
| Vanguard Capital Management LLC | 3,630,252 | $51.9M | 0.0% | +70,683 |
| Paradigm Biocapital Advisors LP | 2,890,397 | $41.3M | 0.8% | −252,040 |
| State Street Corp | 2,357,545 | $33.7M | 0.0% | +260,343 |
| Geode Capital Management, LLC | 2,062,390 | $29.5M | 0.0% | +78,725 |
| Aberdeen Group plc | 2,008,802 | $28.7M | 0.0% | +270,424 |
| Citadel Advisors LLC | 1,977,610 | $28.3M | 0.0% | +71,735 |
| Balyasny Asset Management L.P. | 1,812,358 | $25.9M | 0.0% | +373,621 |
| Parkman Healthcare Partners LLC | 1,288,163 | $18.4M | 1.9% | −66,637 |
| Eventide Asset Management, LLC | 1,245,583 | $17.8M | 0.2% | No change |
| Two Sigma Investments, LP | 1,181,143 | $16.9M | 0.0% | +750,828 |
| Essex Woodlands Management, Inc. | 1,084,857 | $15.5M | 6.1% | No change |
| Orbimed Advisors LLC | 1,069,147 | $15.3M | 0.3% | No change |
| 5AM Venture Management, LLC | 1,050,000 | $15.0M | 5.2% | No change |
| Rosalind Advisors, Inc. | 988,230 | $14.1M | 5.3% | −48,507 |
| Vanguard Portfolio Management LLC | 971,014 | $13.9M | 0.0% | +177,144 |
| Ameriprise Financial Inc | 848,410 | $12.1M | 0.0% | +425,148 |
| Dimensional Fund Advisors LP | 841,746 | $12.0M | 0.0% | +440,625 |
13F reports cover disclosed long positions in U.S. stocks only.
Links
- Websitewww.psivida.com1
- WikipediaEyePoint, Inc.
- WikidataQ7120927
- SEC EDGARCIK 1314102
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15SEC EDGARPaul Ashton, Chief executive officer
- 16SEC EDGARJay S. Duker, President
- 17
- 18
- 19
- 20
- 21
- 22SEC EDGARNancy Lurker, Officer
- 23SEC EDGARLeonard M. Blum, Officer
- 24
- 25
- 26
- 27SEC EDGARAaron Finlay, Secretary
- 28
- 29SEC EDGARPaul Ashton, Managing Director
- 30SEC EDGARReginald J. Sanders, Board member
- 31SEC EDGARFred Hassan, Board member
- 32SEC EDGARStuart Duty, Board member
- 33
- 34SEC EDGARAnthony P. Adamis, Board member
- 35SEC EDGARKaren L. Zaderej, Board member
- 36SEC EDGARDavid R. Guyer, Board member
- 37SEC EDGARWendy F. Dicicco, Board member
- 38SEC EDGARRonald W. Eastman, Board member
- 39SEC EDGARGoran Ando, Board member
- 40SEC EDGARJohn B. Landis, Board member
- 41SEC EDGARKristine Peterson, Board member
- 42SEC EDGARJay S. Duker, Board member
- 43SEC EDGARNancy Lurker, Board member
- 44SEC EDGARDouglas Evan Godshall, Board member
- 45SEC EDGARPaul Hopper, Board member
- 46SEC EDGARPeter G. Savas, Board member
- 47SEC EDGARDavid J. Mazzo, Board member
- 48SEC EDGARKatherine Woodthorpe, Board member
- 49